Calamos Advisors LLC Purchases Shares of 66,431 Inotiv, Inc. (NASDAQ:NOTV)

Calamos Advisors LLC purchased a new stake in shares of Inotiv, Inc. (NASDAQ:NOTV) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 66,431 shares of the company’s stock, valued at approximately $275,000. Calamos Advisors LLC owned approximately 0.26% of Inotiv as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in NOTV. Renaissance Technologies LLC raised its position in Inotiv by 29.9% during the second quarter. Renaissance Technologies LLC now owns 164,164 shares of the company’s stock valued at $273,000 after purchasing an additional 37,800 shares in the last quarter. Geode Capital Management LLC raised its position in Inotiv by 7.7% during the third quarter. Geode Capital Management LLC now owns 250,895 shares of the company’s stock valued at $427,000 after purchasing an additional 18,039 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. raised its position in Inotiv by 612.5% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company’s stock valued at $527,000 after purchasing an additional 109,397 shares in the last quarter. KPP Advisory Services LLC raised its position in Inotiv by 15.8% during the fourth quarter. KPP Advisory Services LLC now owns 275,267 shares of the company’s stock valued at $1,140,000 after purchasing an additional 37,549 shares in the last quarter. Finally, Vantage Point Financial LLC purchased a new position in shares of Inotiv in the fourth quarter worth about $1,393,000. Hedge funds and other institutional investors own 18.17% of the company’s stock.

Insider Transactions at Inotiv

In other Inotiv news, Director Nigel Brown purchased 7,500 shares of Inotiv stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average price of $4.26 per share, for a total transaction of $31,950.00. Following the acquisition, the director now directly owns 65,537 shares in the company, valued at approximately $279,187.62. This trade represents a 12.92 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael J. Harrington purchased 10,000 shares of Inotiv stock in a transaction that occurred on Friday, December 6th. The shares were acquired at an average price of $3.98 per share, for a total transaction of $39,800.00. Following the acquisition, the director now owns 37,500 shares in the company, valued at $149,250. This trade represents a 36.36 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 71,029 shares of company stock worth $314,248 and have sold 26,872 shares worth $112,854. Company insiders own 7.80% of the company’s stock.

Inotiv Stock Down 6.9 %

NOTV opened at $4.18 on Thursday. The company has a market cap of $108.72 million, a P/E ratio of -1.00 and a beta of 3.58. The business’s 50-day moving average price is $4.43 and its 200-day moving average price is $2.80. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 2.29. Inotiv, Inc. has a 12 month low of $1.23 and a 12 month high of $11.42.

Inotiv (NASDAQ:NOTV) last released its quarterly earnings data on Wednesday, February 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative return on equity of 15.86% and a negative net margin of 22.10%. On average, equities analysts expect that Inotiv, Inc. will post -0.75 EPS for the current year.

Inotiv Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.